Intraday Economic News: Housing Starts Drop 10.6% In April

  • ID: 1789083
  • May 2011
  • Standard & Poors
1 of 2

Housing starts dropped 10.6% in April to an annual rate of 523,000 from an upwardly revised 585,000 in March. The consensus was for 570,000 starts. Starts are down 12.8% from April 2010, when the tax rebate program was in full swing. Single-family starts dropped 5.1% to 394,000, and multifamily plunged 28.3% to 114,000. Starts rose in the Midwest and West but fell in the Northeast and South. Weather may have been a factor in the 23.0% decline in the southern states. Permits, which weather affects less than starts, fell 4.0% to 551,000. Although the report is weaker than expected, the upward revision to March starts, from the 549,000 reported a month ago, somewhat offsets the drop. Still, the decline shows...

Standard and Poors RatingsXpress Credit Research provides in-depth coverage of international corporates, financial institutions, insurance companies, utilities, sovereigns and structured finance programs. RatingsXpress Credit Research lets users determine the credit rating of holdings and identify key factors underlying an issuer's creditworthiness, distinguishes the different risk exposures for new and existing deals, and provides an understanding of how their analysts interpret key regulatory, political and environmental events and their economic impact.

Research Type: Commentary
Criteria articles describe the thought process and methodology Standard & Poor's analysts use in determining ratings. These commentary pieces discuss both the quantitative (economic and financial) and qualitative (business analysis and caliber of management) aspects of the analysis, as well as legal issues.

Note: Product cover images may vary from those shown
2 of 2
Note: Product cover images may vary from those shown


  • Quick Help: This Credit Rating Report will be emailed to you.


If you have a more general question about our products please try our



Our Clients

  • Fluidigm Corporation
  • Apple, Inc.
  • CEVA Santé Animale
  • Abbott Laboratories Ltd.
  • Merck Group
  • Allergan Inc.
  • Pfizer Inc.